Sponsors and Exhibitors

Our industry sponsors are at the core of the research and development that contributes to the improvement of patient care. They provide the essential data on products and resources to enable physicians in daily practice and improve patient outcomes.

EAACI’s Hybrid congress will provide sponsors and exhibitors further unique opportunities to reach the EAACI community worldwide. The very latest developments will be presented, discussed and debated during the EAACI Hybrid Congress 2023.

 

For more information on the sponsor opportunities visit our EAACI Sponsor Online Platform (ESOP) by clicking here.

For further sponsor information, please visit our Industry Service Centre – click here (NB: to be able to access this specific area link on the ESOP you must have a uniques user name and password)

Ensure you are at the forefront of research, and support Allergy and Immunology development by sharing Industry activities and attending the following:

Industry Symposia

Delegates are invited to attend a series of Industry Symposia included in the scientific programme of the Congress. All symposia and workshops offer relevant data on up-to-date scientific information and developments from the Industry.

Exhibition

Join us in meeting with key industry experts, exchange knowledge on critical areas of development and research in allergy and immunology.

The onsite and virtual exhibitions will be open according to the main scientific programme timetable, subject to final adjustments.

  • Virtual Exhibition – open from 9 June 2023 until 10 December 2023
  • Start of onsite Exhibition: 9 June 2023 – 9:00 (CET)
  • End of onsite Exhibition: 11 June 2023 – 17:30 (CET)

 

EAACI Mobile App

Company & Product Descriptions available in the EAACI Events mobile app.

The EAACI smartphone app enables you to explore the EAACI Hybrid Congress 2023 programme and exhibition at your fingertips.

 

 

 

 

EAACI Hybrid Congress past list of exhibitors and sponsors:

  • American Academy of Allergy, Asthma & Immunology (AAAAI)
  • Aimmune Therapeutics
  • ALK – Abelló
  • Allergopharma
  • Allergy Therapeutics
  • AstraZeneca PLC
  • BioCryst Pharmaceuticals
  • BluePrint Medicines
  • Bühlmann Labs
  • CSL Behring
  • DBV Technologies
  • Dr. Fooke-Achetrrath Laboratorien GmbH
  • Diater
  • everSens
  • European Respiratory Society (ERS)
  • EUROIMMUN AG
  • ExBio
  • FAES FARMA
  • GlaxoSmithKline plc
  • Hangzhou Zheda Dixun Biological Gene Engineering Co., Ltd.
  • HAL Allergy
  • Helmut Hund GmbH
  • Hycor Biomedical
  • Indoor Biotechnologies
  • Inmunotek
  • KalVista Pharmaceuticals
  • Karger Publishers
  • LETI Pharma
  • Lofarma
  • MacroArray Diagnostics
  • MENARINI GROUP
  • Minaris Medical America, Inc.
  • Merck Sharp & Dohme (MSD)
  • Nestlé Health Science
  • Nestle Purina PetCare
  • Nexkin Medical
  • Noucor
  • Novartis
  • OM Pharma
  • Orion Pharma
  • Pfizer
  • Pharming Group NV
  • Pharvaris GmbH
  • Probelte Pharma
  • Polish Society of Allergology (PTA)
  • Red Maple Trials
  • Roxall
  • Sanofi Regeneron
  • SciBase
  • Stallergenes Greer
  • Takeda
  • Thermo Fisher Scientific
  • World Allergy Organziation (WAO)
  • Wisepress

We are happy to assist companies in selecting the various Industry options at the EAACI Hybrid Congress 2023. Please contact us at sponsors@eaaci.org to discuss the various options available.

Stay in touch

Want to get the news about all the EAACI events?
Subscribe for our events-newsletter here.